HOWARD WEINER to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications HOWARD WEINER has written about Antibodies, Monoclonal, Humanized.
Connection Strength
1.017
-
Dampening of Microglial Activation With Nasal Foralumab Administration in Moderate Alzheimer's Disease Dementia. Clin Nucl Med. 2025 Aug 01; 50(8):756-757.
Score: 0.658
-
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon ?-1a in MS. Neurology. 2016 Oct 04; 87(14):1464-1472.
Score: 0.090
-
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Mult Scler. 2014 Sep; 20(10):1381-90.
Score: 0.077
-
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24; 380(9856):1829-39.
Score: 0.069
-
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24; 380(9856):1819-28.
Score: 0.069
-
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler. 2019 10; 25(12):1605-1617.
Score: 0.026
-
Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol. 2010 Sep; 12(9):985-90.
Score: 0.014
-
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 2009 Jun 02; 72(22):1922-30.
Score: 0.014